U.S. Mortgage Finance Stock News

In August 2026, Immunome, Inc. reported second-quarter and six‑month results showing higher net losses and loss per share than the prior year. On the same day, the company filed a US$38.54 million shelf registration for 1,500,000 common shares tied to an employee stock ownership plan, highlighting its focus on future capital flexibility. Next, we’ll consider how the widened quarterly loss shapes Immunome’s broader investment narrative for investors assessing its long-term prospects. AI is...

Maplebear (CART), which operates Instacart, is back in focus after Academy Sports + Outdoors joined its Marketplace, adding same day delivery from more than 300 sporting goods stores across 21 states. See our latest analysis for Maplebear. The Academy Sports + Outdoors partnership arrives while Maplebear’s share price has risen 18.05% over the past 30 days and 20.89% over the past 90 days, with a 1 year total shareholder return of 14.90%, suggesting momentum is building from a relatively...

We'd be surprised if Bristow Group Inc. ( NYSE:VTOL ) shareholders haven't noticed that the Chief Operating Officer of...

Some Mercury Systems, Inc. ( NASDAQ:MRCY ) shareholders may be a little concerned to see that the President, William...

We wouldn't blame Medpace Holdings, Inc. ( NASDAQ:MEDP ) shareholders if they were a little worried about the fact that...

Anyone interested in Artesian Resources Corporation ( NASDAQ:ARTN.A ) should probably be aware that the Director, Dian...

In mid-August 2026, Synchrony Financial reported second-quarter results that exceeded expectations, raised its 2026 EPS outlook, appointed a Chief AI Officer, and detailed an enterprise-wide collaboration with OpenAI to embed advanced models into shopping, payments, and internal operations. Together, these moves suggest Synchrony is trying to reposition itself as an AI-forward consumer finance platform, using frontier models to rewire how it manages credit risk, develops products, and powers...

Nuvation Bio (NUVB) stock is in focus after the U.S. FDA granted Fast Track Designation to safusidenib for IDH1-mutant glioma, following clinical data showing durable responses and a favorable risk-benefit profile. See our latest analysis for Nuvation Bio. At a latest share price of US$6.93, Nuvation Bio has seen a 46.82% 90 day share price return and a very large 3 year total shareholder return, although the year to date share price return is down 19.23%, which suggests momentum has picked...

Stifel Financial (SF) drew investor attention after its latest market close at $80.96, with recent returns reflecting a mix of short-term weakness and longer-term gains over the past month and the past three months. See our latest analysis for Stifel Financial. Over the past year, Stifel Financial has seen its share price return soften year to date, while its 90 day share price return of 11.53% and 1 year total shareholder return of 8.07% suggest that momentum has been steadier over a longer...

H World Group Limited recently reported its second-quarter and first-half 2026 results, raised full-year 2026 revenue growth guidance to 4%–8% versus 2025, and approved an ordinary cash dividend of about US$275 million, equal to US$0.087 per ordinary share or US$0.87 per ADS, payable to holders on record as of September 8, 2026. By combining a higher revenue outlook with a sizable cash distribution under its 2026 Shareholder Return Plan, the company is signaling confidence in its current...

Why Opendoor Technologies just tapped the bond market Opendoor Technologies (OPEN) has completed a US$650 million zero coupon convertible note offering that runs to August 2030. This financing move directly touches the company’s capital structure, dilution risk, and liquidity profile for shareholders. See our latest analysis for Opendoor Technologies. For context, Opendoor Technologies’ share price is US$3.53 after a 1-day share price return of 1.73%. The stock is down 7.95% over 30 days and...

Oruka Therapeutics (ORKA) has filed a universal shelf registration for up to US$1 billion in common and preferred stock, depositary shares and warrants. This filing gives the company flexibility to raise capital when needed. See our latest analysis for Oruka Therapeutics. Oruka Therapeutics shares trade at US$107.96 after a 78.12% 90 day share price return and a very large 1 year total shareholder return, with recent gains pointing to strong momentum despite a softer 7 day share price return...

Cactus stock has produced strong gains over the past few years, yet its valuation signals are split. The Discounted Cash Flow (DCF) intrinsic value estimate points to a large discount to current pricing, while market multiples and the broader checks suggest the shares are not straightforwardly cheap. Cactus has returned 87.7% over the last 5 years, which puts extra focus on whether the current share price at US$69.43 is still supported by fundamentals. The company’s ability to keep...

Geopolitical risks in the Middle East are keeping energy prices in focus and reminding investors how important reliable power sources are when supply feels uncertain. That spotlight puts nuclear energy stocks back on the radar as a potential way to gain exposure to long term electricity demand and energy security themes. This article walks through three nuclear energy stocks from our screener that many investors are watching closely. The stocks in the article below are just a starting sample,...

Earlier this week, Barclays upgraded American Tower to Overweight from Equal Weight, pointing to stabilizing U.S. tower growth, stronger leasing, international expansion and momentum in its CoreSite data center business. The upgrade has refocused attention on American Tower’s valuation gap, with intrinsic value estimates suggesting the company’s cash-flow profile may be underappreciated. Next, we’ll examine how Barclays’ emphasis on CoreSite’s growing role may influence American Tower’s...

MGM Resorts International (MGM) shares recently closed at $43.74, with the stock roughly flat over the past week and down about 4% over the past month, while still positive year to date. See our latest analysis for MGM Resorts International. Over a longer stretch, MGM Resorts International has a 90 day share price return of 13.91% and a year to date share price return of 19.87%, while the 1 year total shareholder return of 14.92% points to steady but not rapid momentum. If you are comparing...

Yum! Brands recently appointed Stephen (“Steve”) B. Bratspies, former CEO of HanesBrands and ex–Chief Merchandising Officer at Walmart, to its Board of Directors, adding his broad consumer and retail leadership to the company’s governance. With concurrent board roles at Target and Clorox and deep experience in merchandising and operations, Bratspies brings a distinctive multi-brand, multi-channel perspective that could influence Yum!’s execution and oversight of its global restaurant...

Melco Resorts & Entertainment (MLCO) has just reported its second quarter and first half 2026 results, with lower revenue than a year ago but higher net income and earnings per share, drawing renewed attention to the stock. See our latest analysis for Melco Resorts & Entertainment. At a share price of US$5.49, Melco Resorts & Entertainment has seen short term share price support, with a 1 day move of 2.62%. However, the year to date share price return is down 26.9% and the 1 year total...

California Resources (CRC) is back in focus after reporting second quarter 2026 results and issuing fresh production guidance that gives investors more detail on current operations and expected output levels for the rest of the year. See our latest analysis for California Resources. At a share price of $53.24, California Resources has seen its 90 day share price return fall 14.18%. The year to date share price return of 14.77% and 1 year total shareholder return of 9.87% point to momentum...

Assurant (AIZ) has drawn fresh attention after its Board declared a quarterly dividend of US$0.88 per share, coinciding with an analyst upgrade that highlights improved earnings expectations despite existing growth headwinds. See our latest analysis for Assurant. At a share price of US$284.04, Assurant has seen solid momentum, with an 11.47% 90 day share price return and a 33.55% 1 year total shareholder return that reflects income and price gains together. If this mix of income and long term...

Liberty Energy recently reported Q2 2026 adjusted net profit and revenue that surpassed Zacks Consensus Estimates, helped by AI-driven technology and strong operational execution. The company also announced an alliance with SLB to supply modular infrastructure and integrated power generation for global data centers, while launching Liberty Wholesale Commodities to expand its presence in ERCOT power markets. Next, we will examine how the SLB alliance and data center power focus influence...

Northwest Bancshares, Inc. has announced it will redeem on September 15, 2026 all of its outstanding 4.000% Fixed-to-Floating Rate Subordinated Notes due September 15, 2030 at 100% of principal plus accrued and unpaid interest, with payment processed through The Depository Trust Company. This past decision to retire subordinated debt early alters the bank’s capital structure and offers fresh insight into its funding and balance sheet priorities. We’ll now examine how the early subordinated...

Canada–US trade talks have broken down, new tariffs are hitting cross border supply chains, and investors are trying to work out which US domestic industrials might feel pressure and which could gain an edge as production and sourcing patterns adjust. This article looks at three US listed manufacturers from our screener that are closely tied to this story and explains how the news backdrop might influence each stock’s risk and opportunity profile. The three stocks below are just a sample from...

Scholar Rock Holding stock has delivered an exceptionally strong run over the past few years, yet its valuation checks currently lean expensive rather than cheap. After such a move, investors are weighing robust momentum against signals that the shares may already reflect a lot of optimism. Scholar Rock Holding has returned very roughly 8x over the last 3 years, which puts extra focus on whether recent gains are supported by fundamentals. The progress on apitegromab, including the removal of...